Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2b PATHWAY Study
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
12
Citations
NaN
KQI